Altium Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Altium Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-305,000	Closed	-$11.7M	–	88
2023 Q2	$11.7M	Hold	305,000	–	–	8.87%	1
2023 Q1	$7.06M	Sell	305,000 -80,000	-21%	-$1.91M	3.92%	5
2022 Q4	$10.1M	Sell	385,000 -140,000	-27%	-$3.1M	5.13%	3
2022 Q3	$10.3M	Sell	525,000 -90,000	-15%	-$1.81M	3.78%	2
2022 Q2	$10.8M	Buy	615,000 +70,000	+13%	+$1.1M	4.3%	1
2022 Q1	$8.92M	Hold	545,000	–	–	2.98%	5
2021 Q4	$8.89M	Buy	545,000 +80,000	+17%	+$1.14M	2.45%	6
2021 Q3	$5.93M	Buy	465,000 +48,433	+12%	+$637K	1.56%	17
2021 Q2	$5.88M	Buy	416,567 +210,768	+102%	+$3.37M	1.36%	17
2021 Q1	$3.2M	Hold	205,799	–	–	0.89%	45
2020 Q4	$3.26M	Buy	+205,799	New	+$3.1M	1.22%	32

Altium Capital Management's KDNY Position: Q3 2023 in Review

Altium Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 305,000 shares — an estimated $11.7M sold.

Altium Capital Management first reported a position in KDNY in Q4 2020 and held it in 11 quarters. The position peaked at $11.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Altium Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Altium Capital Management sold 305,000 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $11.7M.
Altium Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Altium Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $11.7M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Altium Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.